发明名称 |
Methods for treatment of lymphomas with mutations in cell cycle genes |
摘要 |
The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin/CDK/RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB. |
申请公布号 |
US9241941(B2) |
申请公布日期 |
2016.01.26 |
申请号 |
US201313826056 |
申请日期 |
2013.03.14 |
申请人 |
MEMORIAL SLOAN-KETTERING CANCER CENTER |
发明人 |
Wendel Hans Guido;Oricchio Elisa |
分类号 |
A61K31/519;A61K31/495;G01N33/68;C12Q1/68;A61K45/06;A61K31/404;A61K31/635;G01N33/574 |
主分类号 |
A61K31/519 |
代理机构 |
Pearl Cohen Zedek Latzer Baratz LLP |
代理人 |
Cohen Mark S.;Pearl Cohen Zedek Latzer Baratz LLP |
主权项 |
1. A pharmaceutical composition for treating follicular lymphoma, comprising a combination of a sub-optimal dose of a B-cell lymphoma-2 (BCL2) inhibitor selected from ABT-737 or Obatoclax mesvlate, and a sub-optimal dose of the cyclin-dependent kinase (CDK) inhibitor PD-0332991, wherein the combination is effective for the treatment of a patient identified as having retinoblastoma (RB)-inactivated FL. |
地址 |
New York NY US |